Oruka Therapeutics (FRA:HQ1) Inventories, Work In Process : €0.00 Mil (As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Oruka Therapeutics Inventories, Work In Process?

Work in process is the part of a manufacturer's inventory that is in the production process and has not yet been completed and transferred to the finished goods inventory. Oruka Therapeutics's work in process for the quarter that ended in Dec. 2024 was €0.00 Mil.

Oruka Therapeutics Inventories, Work In Process Historical Data

The historical data trend for Oruka Therapeutics's Inventories, Work In Process can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oruka Therapeutics Inventories, Work In Process Chart

Oruka Therapeutics Annual Data

Trend

Dec24

Inventories, Work In Process

Oruka Therapeutics Semi-Annual Data
	Dec24
Inventories, Work In Process	-

Oruka Therapeutics Inventories, Work In Process Calculation

That part of a manufacturer's inventory that is in the production process and has not yet been completed and transferred to the finished goods inventory. This account contains the cost of the direct material, direct labor, and factory overhead placed into the products on the factory floor. A manufacturer must disclose in its financial statements the cost of its work-in-process as well as the cost of finished goods and materials on hand.

Oruka Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oruka Therapeutics Inc (FRA:HQ1) » Definitions » Inventories, Work In Process

Comparable Companies

Traded in Other Exchanges

ORKA:USA

Address

855 Oak Grove Avenue, Suite 100, Menlo Park, CA, USA, 94025

Website

https://www.orukatx.com

Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.

Oruka Therapeutics Headlines

No Headlines